Publicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (21)

2020

  1. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

    Annals of Oncology, Vol. 31, Núm. 10, pp. 1320-1335

2019

  1. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 849-861

2018

  1. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

    Annals of Oncology, Vol. 29, Núm. 1, pp. 36-43

  2. Integration of oncology and palliative care

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii553

  3. Integration of oncology and palliative care: a Lancet Oncology Commission

    The Lancet Oncology, Vol. 19, Núm. 11, pp. e588-e653

2016

  1. Biosimilars: A position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

    ESMO Open, Vol. 1, Núm. 6

  2. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

    ESMO Open, Vol. 1, Núm. 6

2015

  1. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: Preclinical characterization and phase I clinical trial

    Clinical Cancer Research, Vol. 21, Núm. 1, pp. 49-59

  2. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

    Annals of Oncology, Vol. 26, Núm. 2, pp. 300-306

2014

  1. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: A position paper by the European Society for Medical Oncology (ESMO)

    Annals of Oncology

  2. The current and future role of the medical oncologist in the professional care for cancer patients: A position paper by the European Society for Medical Oncology (ESMO)

    Annals of Oncology, Vol. 25, Núm. 1, pp. 9-15

2013

  1. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

    European Journal of Cancer, Vol. 49, Núm. 11, pp. 2565-2578

2012

  1. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe

    European Journal of Cancer, Vol. 48, Núm. 2, pp. 159-169

  2. Carcinoma of endocrine organs: Results of the RARECARE project

    European Journal of Cancer, Vol. 48, Núm. 13, pp. 1923-1931

  3. Incidence and survival of rare urogenital cancers in Europe

    European Journal of Cancer, Vol. 48, Núm. 4, pp. 456-464

  4. Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002

    European Journal of Cancer, Vol. 48, Núm. 10, pp. 1417-1424

  5. Rare cancers of the head and neck area in Europe

    European Journal of Cancer, Vol. 48, Núm. 6, pp. 783-796

2011

  1. Rare cancers are not so rare: The rare cancer burden in Europe

    European Journal of Cancer, Vol. 47, Núm. 17, pp. 2493-2511

2010

  1. The burden of rare cancers in europe

    Advances in Experimental Medicine and Biology, Vol. 686, pp. 285-303

2003

  1. Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

    Annals of Oncology, Vol. 14, Núm. 3, pp. 441-448